Evidence map›Paper›PMID 39703389›Full record

ArticleFrontiers in pharmacology2024

Integrated bioinformatics and interaction analysis to advance chronotherapies for mental disorders.

Apoorva Bhatnagar, Gupta Raj, Sandip Das, Arpita Kannihali, Eerappa Rajakumara, Greg Murray, Sandipan Ray

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Apoorva BhatnagarDepartment of Biotechnology, Indian Institute of Technology Hyderabad, Sangareddy, Telangana, India.
Gupta RajDepartment of Biotechnology, Indian Institute of Technology Hyderabad, Sangareddy, Telangana, India.
Sandip DasDepartment of Biotechnology, Indian Institute of Technology Hyderabad, Sangareddy, Telangana, India.
Arpita KannihaliDepartment of Biotechnology, Indian Institute of Technology Hyderabad, Sangareddy, Telangana, India.
Eerappa RajakumaraDepartment of Biotechnology, Indian Institute of Technology Hyderabad, Sangareddy, Telangana, India.
Greg MurrayCentre for Mental Health, Swinburne University of Technology, Melbourne, VIC, Australia.
Sandipan RayDepartment of Biotechnology, Indian Institute of Technology Hyderabad, Sangareddy, Telangana, India.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Introduction: Robust connections have been identified between the pathophysiology of mental disorders and the functioning of the circadian system. The overarching objective of this study was to investigate the potential for circadian rhythms to be leveraged for therapeutics in mental disorders. Methods: We considered two approaches to chronotherapy-optimal timing of existing medications ("clocking the drugs") and redressing circadian abnormalities with small molecules ("drugging the clock"). We assessed whether circadian rhythm-modulating compounds can interact with the prominent drug targets of mental disorders utilizing computational tools like molecular docking and molecular dynamics simulation analysis. Results: Firstly, an analysis of transcript-level rhythmic patterns in recognized drug targets for mental disorders found that 24-hour rhythmic patterns were measurable in 54.4% of targets in mice and 35.2% in humans. We also identified several drug receptors exhibiting 24-hour rhythmicity involved in critical physiological pathways for neural signaling and communication, such as neuroactive ligand-receptor interaction, calcium signaling pathway, cAMP signaling pathway, and dopaminergic and cholinergic synapses. These findings advocate that further research into the timing of drug administration in mental disorders is urgently required. We observed that many pharmacological modulators of mammalian circadian rhythms, including KL001, SR8278, SR9009, Nobiletin, and MLN4924, exhibit stable binding with psychotropic drug targets. Discussion: These findings suggest that circadian clock-modulating pharmacologically active small molecules could be investigated further for repurposing in the treatment of mood disorders. In summary, the present analyses indicate the potential of chronotherapeutic approaches to mental disorder pharmacotherapy and specify the need for future circadian rhythm-oriented clinical research.

Indexed as

chronotherapeuticscircadian rhythminteraction analysismental disordersmolecular dynamics simulation

Identifiers

PMID39703389
PMCPMC11655208

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.